NCT06848348 Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
| NCT ID | NCT06848348 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Dogwood Therapeutics Inc. |
| Condition | Chemotherapy Induced Neuropathic Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 240 participants |
| Start Date | 2025-02-21 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 240 participants in total. It began in 2025-02-21 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections. After that, subjects may have the option to enter an Open Label extension phase, where available, in which all subjects will receive Halneuron.
Eligibility Criteria
Inclusion Criteria: * Male or female patients aged ≥18 years. * Neuropathic pain has been present and is attributed to platinum and/or taxane chemotherapy. * Patient has received a cancer chemotherapy regimen that included taxanes and/or platinum and has no active or discernible disease progression. Exclusion Criteria: * Current neuropathic pain with symptoms similar to CINP but attributed to causes other than platinum or taxane chemotherapy. * Patients who have received HAL at any time prior to screening.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06848348 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chemotherapy Induced Neuropathic Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06848348 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06848348 currently recruiting?
Yes, NCT06848348 is actively recruiting participants. Contact the research team at Mehran@dwtx.com for enrollment information.
Where is the NCT06848348 trial being conducted?
This trial is being conducted at Sheffield, United States, Glendale, United States, Phoenix, United States, Fair Oaks, United States and 11 additional locations.
Who is sponsoring the NCT06848348 clinical trial?
NCT06848348 is sponsored by Dogwood Therapeutics Inc.. The trial plans to enroll 240 participants.